Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.ncbi.nlm.nih.gov › pmc › articlesStem-cell therapy and platelet-rich plasma in regenerative...

   www.ncbi.nlm.nih.gov › pmc › articles

   3 wrz 2018 · Among the several therapeutic strategies available, the use of platelet-rich plasma (PRP) and stem cell (SC) represents the mainstream technologies to repair and rejuvenate the damaged tissue caused due to injury or chronic diseases.

2. www.ncbi.nlm.nih.gov › pmc › articlesThrombocytopenia and Therapeutic Strategies after Allogeneic ...

   www.ncbi.nlm.nih.gov › pmc › articles

   2 mar 2022 · Thrombopoietin receptor agonists are currently available to stimulate platelet production. Some small retrospective studies have reported their potential efficacy in an allogeneic stem cell transplant setting, confirming good tolerability.

3. ashpublications.org › thehematologist › articleThrombocytopenia Post-transplantation: A Clinical Challenge in...

   ashpublications.org › thehematologist › article

   • Zapisane w pamięci cache

   10 kwi 2019 · Dr. Serena Marotta and colleagues describe utilizing eltrombopag specifically for persistent cytopenia and poor graft function in 12 patients at a single European center in this retrospective series. The treatment was started at a dose of 50 mg/d and uptitrated to 150 mg to increase response rates.

4. www.nature.com › articles › s41409/022/01726-2Delayed platelet recovery and mortality after allogeneic stem...

   www.nature.com › articles › s41409/022/01726-2

   28 maj 2022 · In our study although CD34 + cell doses influenced platelet recovery, neither CD34 +, or CD3 + cell dose impacted TRM, or overall mortality. However, DPR was significantly associated with TRM...

5. ashpublications.org › blood › articleRomiplostim in patients undergoing hematopoietic stem cell ...

   ashpublications.org › blood › article

   • Zapisane w pamięci cache

   16 sty 2020 · Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.

6. www.ncbi.nlm.nih.gov › pmc › articlesChallenges and Advances in Managing Thrombocytopenic Cancer...

   www.ncbi.nlm.nih.gov › pmc › articles

   11 mar 2021 · The mainstay of managing severe chemotherapy-induced thrombocytopenia (CIT) in cancer is the use of platelet transfusions. While prophylactic platelet transfusions reduce the bleeding rate, multiple unmet needs remain, such as high residual rates of bleeding, and anticancer treatment dose reductions/delays.

7. stemcellsjournals.onlinelibrary.wiley.com › doi › 10Therapeutic use of red blood cells and platelets derived from...

   stemcellsjournals.onlinelibrary.wiley.com › doi › 10

   1 lis 2021 · Red blood cells (RBCs) and platelets derived from stem cells are possible solutions to the increasing demand for blood transfusion.